Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Liu

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
International Journal of Radiation Oncology, Biology, Physics|July 15, 2022
Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 TrialSarah Baker, Benjamin Mou, Will Jiang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 23, 2025
Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapyEmily O'Reilly, Eshawn Johal, Haley Clark, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2022
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 TrialSarah Baker, Will Jiang, Benjamin Mou, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2025
The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 TrialSarah Baker, Curtis Leclerc, Hanna Atmanspacher-Wirth, et al.
International Journal of Radiation Oncology, Biology, Physics|November 28, 2008
Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancerW James Morris, Mira Keyes, David Palma, et al.
BMC Cancer|October 6, 2018
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5Robert Olson, Mitchell Liu, Alanah Bergman, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2019
Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized TrialRobert Olson, Suresh Senan, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized TrialX Melody Qu, Yujie Chen, Gregory S Zaric, et al.
The Lancet. Oncology|June 14, 2021
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trialArjun Sahgal, Sten D Myrehaug, Shankar Siva, et al.
Lancet (London, England)|April 16, 2019
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialDavid A Palma, Robert Olson, Stephen Harrow, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
International Journal of Radiation Oncology, Biology, Physics|July 15, 2022
Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 TrialSarah Baker, Benjamin Mou, Will Jiang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 23, 2025
Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapyEmily O'Reilly, Eshawn Johal, Haley Clark, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2022
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 TrialSarah Baker, Will Jiang, Benjamin Mou, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2025
The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 TrialSarah Baker, Curtis Leclerc, Hanna Atmanspacher-Wirth, et al.
International Journal of Radiation Oncology, Biology, Physics|November 28, 2008
Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancerW James Morris, Mira Keyes, David Palma, et al.
BMC Cancer|October 6, 2018
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5Robert Olson, Mitchell Liu, Alanah Bergman, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2019
Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized TrialRobert Olson, Suresh Senan, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized TrialX Melody Qu, Yujie Chen, Gregory S Zaric, et al.
The Lancet. Oncology|June 14, 2021
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trialArjun Sahgal, Sten D Myrehaug, Shankar Siva, et al.
Lancet (London, England)|April 16, 2019
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialDavid A Palma, Robert Olson, Stephen Harrow, et al.
Pageof 10